Roxadustat Treatment After PCI Among Patients With ST-Segment Elevation Myocardial Infarction: A Randomized - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Randomized Evaluation of Roxadustat Therapy Following PCI in Patients With ST-Segment Elevation Myocardial Infarction

  • By

  • Weiwei Quan

  • Yueying Wang

  • Min Zhang

  • Tianqi Zhu

  • Jinzhou Zhu

  • Xiaoqun Wang

  • Zhengbin Zhu

  • Run Du

  • Fenghua Ding

  • Jingwei Ni

  • Shuo Feng

  • Hongyang Xie

  • Lili Liu

  • Yuehua Fang

  • Xuezheng Qu

  • Ruiyan Zhang

  • Xiaoxiang Yan

  • October 9, 2026

Share

  • 1

    The ROXAMI trial tested whether roxadustat started after primary PCI could reduce infarct size and improve functional outcomes in patients with STEMI.

  • 2

    This prospective, open-label, randomized trial enrolled adults with STEMI who presented within 12 hours of symptom onset and underwent primary PCI.

  • 3

    Participants were randomized 1:1 to standard care with or without roxadustat, initiated within 2 hours after PCI at 100 mg 3 times weekly for 2 weeks.

  • 4

    The prespecified primary end point was infarct size as a percentage of left ventricular volume, assessed by PET and MRI at a mean of 30 days after presentation.

  • 5

    Prespecified secondary end points included major adverse cardiovascular events, myocardial injury markers, echocardiographic measures, and myocardial fibroblast activation parameters.

Original Source(s)

Related Content